Pediatrix Medical

Q1 FY2026 EarningsQ2 FY2026 update signals stability amidst sector-wide volatility, with payor mix remaining unchanged and in-line with historical trends. Management reaffirmed full-year 2026 Adjusted EBITDA guidance of $280M–$300M, which aligns with consensus expectations. While detailed Q2 financials will be released on August 4, the preliminary confirmation of revenue-related trends and payor stability provides a positive read-through for earnings consistency.